Skip to main content
. Author manuscript; available in PMC: 2017 Aug 6.
Published in final edited form as: PET Clin. 2017 Jul;12(3):269–288. doi: 10.1016/j.cpet.2017.02.001

Fig. 1.

Fig. 1

89Zr-trastuzumab biodistribution in time. (A–C) Three 89Zr-trastuzumab scans of a patient already on tras-tuzumab treatment (cohort 3) show the increase over time in the tumor/nontumor ratio with regard to uptake of the tracer. Arrow indicates 89Zr-trastuzumab uptake in the only lesion. p.i., postinjection; 89Zr, zirconium-89. (From Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87(5):588; with permission.)